Clinical trial

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

NCT07527806

Drugs and interventions used in this trial

8 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Trastuzumab (Herceptin) Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pertuzumab Normalized identity: pertuzumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Combination product: Trastuzumab + Pertuzumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Docetaxel or Nab-paclitaxel Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention CDK4/6 inhibitor Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Aromatase Inhibitor (AI) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADC Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-05-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

Trastuzumab (Herceptin)DRUG

PertuzumabDRUG · verified · RxNorm: pertuzumab

Combination product: Trastuzumab + PertuzumabDRUG

Docetaxel or Nab-paclitaxelDRUG

carboplatinDRUG · verified · RxNorm: carboplatin

CDK4/6 inhibitorDRUG

Aromatase Inhibitor (AI)DRUG

ADCDRUG

Sponsors & collaborators

Peking University Cancer Hospital & Institutelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07527806 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.